Gilteritinib

CHEMBL3301622 Phase 4 Onaylandı Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

552.7 g/mol

LogP

3.5

Phase

4

A small molecule kinase inhibitor targeting FLT3 mutations in cancer cells, used to treat relapsed or refractory acute myeloid leukemia with these specific genetic alterations. By blocking mutated FLT3 signaling, it prevents leukemia cells from receiving growth signals they depend on. Genetic testing for FLT3 mutations is required before prescribing this medication.

Moleküler Ağırlık

552,7000 g/mol

LogP

3,50

TPSA

121,00 Å²

Lipinski RO5

Geçer

Terapötik Alanlar

Non-Small Cell Lung Cancer Lymphoma Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Yapı

SVG PNG

Cite this structure

Embed this structure

SMILES

CCc1nc(C(N)=O)c(Nc2ccc(N3CCC(N4CCN(C)CC4)CC3)c(OC)c2)nc1NC1CCOCC1

InChI

InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)

Molecular Formula

C29H44N8O3

HBD / HBA

3 / 10

Döndürülebilir Bağlar

9

Ağır Atomlar

40

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

A small molecule kinase inhibitor targeting FLT3 mutations in cancer cells, used to treat relapsed or refractory acute myeloid leukemia with these specific genetic alterations. By blocking mutated FLT3 signaling, it prevents leukemia cells from receiving growth signals they depend on. Genetic testing for FLT3 mutations is required before prescribing this medication.

Yes, Gilteritinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3301622. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 49803313. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Hasta dostu bilgi mi arıyorsunuz?

Gilteritinib PillFYI'da

Yapı

Hızlı Veriler

Formül: C29H44N8O3
Eş Anlamlılar: 1

Dış Bağlantılar

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.